Part 2 of Truffle Report's interview series with Kernel CEO, Bryan Johnson to discuss their Cybin partnership and the future of mental health.
This week at Kernel, we’ve been circulating an executive summary on the cognitive effects of Covid-19, some suspected mechanisms, and exploring what we can do about it.
Bryan Johnson sits down with Truffle Report to discuss Kernel's partnership with Cybin and the impact psychedelics and neuroscience can make together. (Part 1)
Cami Russo writes about Kernel and other pioneers of using novel psychedelic drugs as treatment for mental health.
Kernel and Cybin Partner, Charting New Course in Psychiatry with Kernel Flow's Breakthrough Neuroimaging for Use in Psychedelic Pharmaceutical Therapies
IEEE Spectrum predicts advances in Mars missions, wearable brain scanners, and quantum communications
We recently announced the availability of our first 50 Kernel Flow devices, and the response and enthusiasm far exceeded our expectations. Since, we have committed 23 Flow systems to elite academic and industry groups whose research ideas are diverse, ambitious, and extraordinarily exciting.
This week we ran our first sessions combining Kernel Flow and Virtual Reality (VR). The pairing of Kernel Flow—the world’s first full-head coverage TD-fNIRS system—and VR is of particular interest to us as we build a scalable software and hardware ecosystem for both organizations and individuals.